Skip to content

Polymorphic malware can shut down healthcare systems

Cyber threats in healthcare: The growing danger of polymorphic malware. The healthcare industry is facing increasingly sophisticated cyberattacks, with polymorphic malware representing a particularly menacing development. This type of malicious software can alter its appearance and structure with each execution, making it difficult for traditional security systems to detect[8]. Current Threat Landscape According to a recent study by Sophos, 67% of healthcare organizations surveyed were affected by ransomware attacks in 2024, a significant increase from 60% the previous year[1]. This rise contrasts with an industry-wide trend where the attack rate decreased from 66% to 59%[7]. The World Economic Forum reports an average of 1,684 attacks per week on the healthcare sector in the first quarter of 2023, a 22% increase year-over-year[6]. These figures underscore the growing threat to the industry. Polymorphic Malware and AI The development of polymorphic malware is being driven by the use of AI technologies such as ChatGPT… 

more »Polymorphic malware can shut down healthcare systems

Cyberattack paralyzes IT systems of Waren Clinic

The clinic in Waren (Müritz) has fallen victim to a large-scale cyberattack. All central servers of the hospital were encrypted by a criminal crypto-raid, rendering all IT systems, including email services, inoperable[1][2]. Impact and Emergency Measures The attack affects not only the Waren clinic but also other facilities of the Johannesstift Diakonie, to which the hospital belongs. Despite the massive disruption, operations in all affected facilities continue to run stably thanks to activated emergency concepts[1]. However, scheduled procedures must be postponed at some locations[1]. Clinic Management's Response Dr. med. Lutz Fritsche, Medical Director at Johannesstift Diakonie, emphasizes the ever-present danger of such attacks: "IT security is a constant race against globally networked criminal hackers. A threat that essentially all companies are exposed to."[1] So far, there is no indication that data has been stolen[1]. Ongoing Investigations and Recovery Efforts An external Critical Response Team… 

more »Cyberattack paralyzes IT systems of Waren Clinic

Diabetes and heart failure: The overview

  • News

Diabetes and heart failure are two closely related conditions that can influence and exacerbate each other. Patients with diabetes have a significantly increased risk of developing heart failure. Conversely, the prevalence of diabetes is increased in heart failure patients. Studies show that diabetics have a two to four times higher risk of developing heart failure than non-diabetics[7]. Particularly alarming is that a cardiological screening of diabetes patients revealed that 28% of them suffered from undiagnosed heart failure[7]. This underscores the need for early screening for heart failure in diabetics. The prognosis for patients with both conditions is significantly worse. According to data from Austria, patients with diabetes and heart failure have approximately twice the risk of dying from a cardiovascular event compared to patients with heart failure without diabetes[4]. Furthermore, early kidney disease, which is often associated with diabetes, can reduce the overall life expectancy in male diabetics… 

more »Diabetes and Heart Failure: The Overview

Axis Health System Affected by "Cyber Incident"

Axis Health System, based in Colorado, is facing a "cyber incident," according to a notice on the provider's website. The provider, which offers primary care, dental services, behavioral health, and substance abuse treatment at 13 locations in southwestern and western Colorado, stated in the post that the incident is still under investigation. Axis's primary care patient portal is offline, according to the provider. Axis stated that patients would be notified by email if their data had been compromised. Axis Health System

Galactic53 Trial Data Is Published in Scientific Reports

NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced that the Galactic53 study of VILTEPSO® (generic name: viltolarsen) – a treatment for Duchenne muscular dystrophy (Duchenne) – has been published in the journal Scientific Reports. The paper, “Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy,” contains data from an open-label multicenter study, which was the first to evaluate the effects of viltolarsen on pulmonary function in participants with Duchenne. Ten ambulatory and ten nonambulatory participants ages eight years and older – with a confirmed deletion of the dystrophin gene that could be treated by exon 53 skipping – received 80 mg/kg of the drug intravenously once weekly for 48 weeks. Safety was evaluated as the primary endpoint, and pulmonary and motor function were evaluated as secondary efficacy endpoints.… 

more »Galactic53 Trial Data Is Published in Scientific Reports

Skin Cancer: CRISPR Tools Can Disable Gene Mutations

  • News

In a potential breakthrough for melanoma patients, researchers at the Gene Editing Institute of ChristianaCare have used CRISPR gene editing tools to disable a gene mutation that is common in aggressive forms of this dangerous skin cancer and renders promising treatments ineffective. The study, published in the CRISPR Journal, focused on melanoma cells from a patient whose cancer had developed a mutation that causes drugs that can slow the disease's progression to stop working. The scientists used CRISPR gene editing tools to disable the mutation, restoring cancer cells' sensitivity to treatment in a way that appears to minimize the risk of dangerous side effects. This approach is tumor-specific, targeting melanoma tumor cells and leaving healthy cells alone, thereby restoring sensitivity to cancer drugs only in the tumor cells. "This study confirms our previous findings in lung cancer that CRISPR gene editing can disable genes involved in resistance to...

more »Skin Cancer: CRISPR Tools Can Disable Gene Mutations

Study: Gout is purely genetic

Gout is a chronic disease where the main cause is genetic rather than the lifestyle of the person affected, according to a large international study. Led by researchers at the University of Otago, the genome-wide association study, published in Nature Genetics, analyzed the genetic information of 2.6 million people. The researchers analyzed combined DNA datasets from around the world. About three-quarters of the data came from customers of 23andMe, Inc., a direct-to-consumer genetic and preventive healthcare company that had agreed to participate in the study. They found that genetic predisposition plays a major role in why some people develop gout and most others do not. "Gout is a chronic disease with a genetic cause and not the fault of the person affected – the myth that gout is caused by lifestyle or diet...

more »Study: Gout is Purely Genetic

NBCA Announces Endorsement of Inari Medical DEFIANCE Trial

In honor of World Thrombosis Day, the National Blood Clot Alliance („NBCA“), the nation’s leading patient advocacy organization dedicated to advancing the prevention, early diagnosis, and treatment of venous blood clots, is proud to announce its endorsement of DEFIANCE, a prospective, multinational, randomized controlled trial („RCT“) from Inari Medical that aims to advance clinical research for patients suffering from Deep Vein Thrombosis („DVT“). The DEFIANCE trial will evaluate and compare the clinical outcomes of certain symptomatic DVT patients following treatment with mechanical thrombectomy using Inari Medical’s ClotTriever System to treatment with anticoagulation medication alone. The DEFIANCE trial will enroll up to 300 patients at up to 60 global sites. The trial’s primary endpoint will be a composite of: 1) treatment failure or therapy escalation rates, and 2) severity of PTS assessed at the 6-month follow-up. The study’s rigorous design will… 

more »NBCA Announces Endorsement of Inari Medical DEFIANCE Trial

Hologic Acquires Gynesonics for $350 Million

Hologic, Inc. (Nasdaq: HOLX), a global champion of women’s health, today announced that it has signed a definitive agreement to acquire Gynesonics, Inc. (Gynesonics®). The company is a privately held medical technology company focused on developing minimally invasive solutions for women’s health. The purchase price is approximately $350 million. Gynesonics, based in Redwood City, Calif., develops and markets the Sonata® system, a technology for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. The Sonata system combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in a no-incision procedure.

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences, Inc. („Anixa“ or the „Company“) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has administered the second dose of its CAR-T therapy to an individual patient. This follows a positive response after the initial treatment in the ongoing Phase 1 clinical trial of its chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. The study is being conducted in collaboration with Moffitt Cancer Center. Previously, Anixa and Moffitt received approval for a single-patient IND application, allowing the administration of a second dose to a patient whose tumor biopsy revealed cellular infiltration and necrosis, indicating biological activity of the CAR-T therapy. After the first infusion, the patient remained stable, did not require alternative treatment and her quality of life was good, leading to the decision to administer a second dose… 

more »Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial